What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The CAPItello-281 trial showed a statistically significant improvement in rPFS with a hazard ratio of 0.81, but the overall survival data is immature and the clinical meaningfulness of the rPFS benefit is questioned due to variability in sensitivity analyses and lack of head-to-head comparisons with other treatments.
Does the economic case hold at the expected price? — Cost effectiveness
No prostate-specific cost-utility analysis, QALY estimate, or ICER was identified in the review. NICE appraisal is awaiting development.
Is there quality-of-life evidence payers weigh? — Quality of life
FACT-P scores showed minimal differences between treatment arms, with early physical well-being deterioration observed in the capivasertib arm. No EQ-5D utility scores were reported, limiting the assessment of HRQoL impact.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Capivasertib treatment resulted in a substantial incremental toxicity burden, including higher rates of diarrhea, cutaneous reactions, and hyperglycemia, leading to dose interruptions and discontinuations.
Was the drug compared against what payers expect? — Comparator Selection
The trial used a clinically strong comparator of abiraterone/prednisone/ADT, aligning with current guidelines, but did not compare directly with other ARPI or triplet strategies.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was representative of the target population, but important exclusions and limited representation of Black patients affect generalizability. Subgroup analyses on PTEN loss were hypothesis-generating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment fits into the existing care pathway with the requirement of PTEN testing and metabolic monitoring. No major infrastructure changes are needed, but specific monitoring protocols are required.
Are the wider system costs understood? — Resource Use and Cost Implications
The treatment requires additional resources for PTEN testing and metabolic monitoring, but no quantified budget impact or cost savings from avoided events were identified.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a large, randomized, double-blind phase III trial with a strong design, but the magnitude of benefit is uncertain due to variability in sensitivity analyses and immature OS data.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is high uncertainty regarding the magnitude of rPFS benefit and PTEN threshold sensitivity. No economic sensitivity analyses were available.
